Basiliximab in Moderate to Severe Ulcerative Colitis

ClinicalTrials.gov ID: NCT00430898

Public ClinicalTrials.gov record NCT00430898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, With Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety, effectiveness and pharmacokinetics of two levels of intravenous basiliximab in ulcerative colitis, compared to placebo.

Study identification

NCT ID: NCT00430898
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Cerimon Pharmaceuticals; Industry
Enrollment: 181 participants

Conditions and interventions

Conditions

Ulcerative Colitis

Interventions

Basiliximab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2007 (Type not available)
Primary completion: Sep 2008 (Actual)
Completion: Sep 2008 (Actual)
Last update posted: Dec 18, 2008

2007 – 2008

United States locations

U.S. sites: 25
U.S. states: 17
U.S. cities: 25

Facility	City	State	ZIP	Site status
Not listed	Anaheim	California	—	—
Not listed	Roseville	California	95661	—
Not listed	Golden	Colorado	—	—
Not listed	Littleton	Colorado	—	—
Not listed	Hollywood	Florida	—	—
Not listed	Jacksonville	Florida	—	—
Not listed	Winter Park	Florida	32789	—
Not listed	Atlanta	Georgia	—	—
Not listed	Chicago	Illinois	60637	—
Not listed	Urbana	Illinois	61801	—
Not listed	Indianapolis	Indiana	46202	—
Not listed	Topeka	Kansas	66606	—
Not listed	Lexington	Kentucky	40536	—
Not listed	Boston	Massachusetts	02114	—
Not listed	Troy	Michigan	—	—
Not listed	Egg Harbor Twp	New Jersey	08234	—
Not listed	Great Neck	New York	—	—
Not listed	New York	New York	—	—
Not listed	Fargo	North Dakota	58104	—
Not listed	Cleveland	Ohio	44195	—
Not listed	Sewickley	Pennsylvania	15143	—
Not listed	Germantown	Tennessee	—	—
Not listed	Fort Worth	Texas	76104	—
Not listed	Galveston	Texas	—	—
Not listed	Houston	Texas	77090	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00430898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 18, 2008 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00430898 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →